Celebrating 50 Years of Innovation

For the past five decades, Lerner David has thrived as an intellectual property boutique dealing with all aspects of IP. IP is not just our specialty; it is our passion and purpose. We assist a diverse client base at the forefront of the Fourth Industrial Revolution (4IR), protecting groundbreaking technologies from AI to 3D printing; renewable energy to autonomous vehicles; FinTech to telecommunications; pharmaceuticals to life-saving medical therapies. We safeguard some of the world’s leading brands. And we fight for our clients’ rights before the courts and administrative tribunals of the world.

As the world enters 4IR and we embark on our next 50 years, Lerner David stands at the ready to help innovators protect and bring tomorrow’s emerging technologies to life today.

Practices

Helping Clients Succeed

Lerner David Defeats Motion for Summary Judgement in Trademark Case

On December 20, 2018, Judge Wolfson in the United States District Court, District of New Jersey, denied the opponent’s summary judgment motion on all grounds that our client’s trademark is invalid. In the opponent’s motion, it argued that our client’s mark is invalid because 1) it creates a likelihood of confusion with other, third-party marks; 2) our client never actually used the mark in commerce; 3) our client committed fraud on the PTO in attempting to obtain registration; and 4) the defense of laches bars our client from asserting a trademark infringement claim. The Court addressed each o...

Kashiv and Amneal Prevail in Fourth IPR, Invalidating All Challenged Claims of OxyContin® Patents

In a Final Written Decision issued in favor of Lerner David clients Kashiv Pharma, LLC and Amneal Pharmaceuticals, LLC, the Patent Trial and Appeal Board ("PTAB") held all challenged claims of U.S. Patent No. 9,034,376 invalid on both asserted grounds. The '376 Patent is directed to a sustained release formulation of oxycodone HCl, marketed by Purdue Pharma as OxyContin®, and is one of twenty patents that Purdue has asserted against Kashiv's ANDA directed to its own abuse-deterrent formulation of oxycodone. This marks the fourth IPR win for Kashiv against this family of patents. Collectively, ...

Global Trademark Skills Recognized

A global outlook characterises the thriving practice at Lerner David. This New Jersey boutique has its sights firmly trained on Asia; offices in China and Japan have brought in waves of new work, with many businesses looking for truly international trademark strategies. After determining which jurisdictions are most important to their clients, the team’s canny practitioners employ first-hand experience of the integrity of different trademark offices and courts around the world and then come up with a sound way forward. Of late, they have been particularly busy wrestling domain names away from ...

Amneal and Kashiv Prevail, Again, in Invalidating Additional OxyContin® Patent

In a Final Written Decision issued in favor of Lerner David clients Amneal Pharmaceuticals, LLC and Kashiv Pharma, LLC, the Patent Trial and Appeal Board ("PTAB") held all challenged claims of U.S. Patent No. 9,034,376 invalid. The '376 Patent is directed to a sustained release formulation of oxycodone HCl, marketed by Purdue Pharma as OxyContin®, and is one of twenty patents that Purdue has asserted against Kashiv's ANDA directed to its own abuse-deterrent formulation of oxycodone. The case is Amneal Pharmaceuticals, LLC v. Purdue Pharma, L.P. et al., Case No. IPR2016-01413, (Jan. 17, 2018).

More Successes

DecIPhered

DecIPhered is our IP Newsletter to keep you up-to-date on prominent IP issues.

Subscribe

More DecIPhered

Celebrating 50 Years of Innovation

Helping Clients Succeed

Lerner David Defeats Motion for Summary Judgement in Trademark Case

Kashiv and Amneal Prevail in Fourth IPR, Invalidating All Challenged Claims of OxyContin® Patents

Global Trademark Skills Recognized

Amneal and Kashiv Prevail, Again, in Invalidating Additional OxyContin® Patent

SCOTUS Holds “Secret Sales” May Trigger On-Sale Patent Bar

Copyright Registration - A Requirement to File Suit Says The Supreme Court

Supreme Court Upholds Award of Lost Foreign Profits For Patent Infringement

Supreme Court Rules Inter Partes Decisions Are Here To Stay, With Modifications